EP1605935A4 - Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system - Google Patents
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous systemInfo
- Publication number
- EP1605935A4 EP1605935A4 EP04717992A EP04717992A EP1605935A4 EP 1605935 A4 EP1605935 A4 EP 1605935A4 EP 04717992 A EP04717992 A EP 04717992A EP 04717992 A EP04717992 A EP 04717992A EP 1605935 A4 EP1605935 A4 EP 1605935A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- disorders
- compositions
- management
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45237403P | 2003-03-06 | 2003-03-06 | |
US452374P | 2003-03-06 | ||
PCT/US2004/006782 WO2004080393A2 (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1605935A2 EP1605935A2 (en) | 2005-12-21 |
EP1605935A4 true EP1605935A4 (en) | 2009-05-20 |
Family
ID=32990646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04717992A Withdrawn EP1605935A4 (en) | 2003-03-06 | 2004-03-05 | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1605935A4 (en) |
JP (1) | JP2006519875A (en) |
KR (1) | KR100831545B1 (en) |
CN (1) | CN1780616B (en) |
AU (1) | AU2004220607B2 (en) |
BR (1) | BRPI0408113A (en) |
CA (1) | CA2517845A1 (en) |
IL (1) | IL170710A0 (en) |
MX (1) | MXPA05009435A (en) |
NZ (1) | NZ542408A (en) |
WO (1) | WO2004080393A2 (en) |
ZA (1) | ZA200507322B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
EA037187B1 (en) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Method and composition for treating a cognitive disorder |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | Methods and compositions for improving cognitive function |
AU2016268096B2 (en) | 2015-05-22 | 2021-04-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
WO2019078915A1 (en) * | 2017-10-18 | 2019-04-25 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
EP4241774A1 (en) * | 2020-11-04 | 2023-09-13 | Gliacelltech Inc. | Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001348A2 (en) * | 1993-07-02 | 1995-01-12 | Celgene Corporation | Imides as inhibitors of tnp alpha |
WO1997008143A1 (en) * | 1995-08-29 | 1997-03-06 | Celgene Corporation | Inhibitors of tumor necrosis factor alpha |
WO1999006041A1 (en) * | 1997-07-31 | 1999-02-11 | Celgene Corporation | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
WO2001034606A1 (en) * | 1999-11-12 | 2001-05-17 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
WO2001049321A1 (en) * | 1999-12-31 | 2001-07-12 | Tobinick Edward L | Tnf inhibitors for the treatment of neurological, retinal and muscular disorders |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2005094218A2 (en) * | 2004-03-05 | 2005-10-13 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
AR003951A1 (en) * | 1995-05-26 | 1998-09-30 | Pfizer | SYNERGIC PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF PARKINSON'S DISEASE AND COMPOSITIONS TO PREPARE IT. |
JP3568749B2 (en) * | 1996-12-17 | 2004-09-22 | 株式会社デンソー | Dry etching method for semiconductor |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CA2481385A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
-
2004
- 2004-03-05 EP EP04717992A patent/EP1605935A4/en not_active Withdrawn
- 2004-03-05 JP JP2006509174A patent/JP2006519875A/en active Pending
- 2004-03-05 BR BRPI0408113-7A patent/BRPI0408113A/en not_active IP Right Cessation
- 2004-03-05 ZA ZA200507322A patent/ZA200507322B/en unknown
- 2004-03-05 NZ NZ542408A patent/NZ542408A/en unknown
- 2004-03-05 CN CN2004800118192A patent/CN1780616B/en not_active Expired - Fee Related
- 2004-03-05 AU AU2004220607A patent/AU2004220607B2/en not_active Ceased
- 2004-03-05 MX MXPA05009435A patent/MXPA05009435A/en not_active Application Discontinuation
- 2004-03-05 WO PCT/US2004/006782 patent/WO2004080393A2/en active Application Filing
- 2004-03-05 KR KR1020057016598A patent/KR100831545B1/en not_active IP Right Cessation
- 2004-03-05 CA CA002517845A patent/CA2517845A1/en not_active Abandoned
-
2005
- 2005-09-06 IL IL170710A patent/IL170710A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001348A2 (en) * | 1993-07-02 | 1995-01-12 | Celgene Corporation | Imides as inhibitors of tnp alpha |
WO1997008143A1 (en) * | 1995-08-29 | 1997-03-06 | Celgene Corporation | Inhibitors of tumor necrosis factor alpha |
WO1999006041A1 (en) * | 1997-07-31 | 1999-02-11 | Celgene Corporation | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
WO2001034606A1 (en) * | 1999-11-12 | 2001-05-17 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
WO2001049321A1 (en) * | 1999-12-31 | 2001-07-12 | Tobinick Edward L | Tnf inhibitors for the treatment of neurological, retinal and muscular disorders |
US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003080048A1 (en) * | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2005094218A2 (en) * | 2004-03-05 | 2005-10-13 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
Non-Patent Citations (2)
Title |
---|
MOGI M ET AL: "Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 165, no. 1-2, 3 January 1994 (1994-01-03), pages 208 - 210, XP024375768, ISSN: 0304-3940, [retrieved on 19940103] * |
SRIRAM KRISHNAN ET AL: "Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SEP 2002, vol. 16, no. 11, September 2002 (2002-09-01), pages 1474 - 1476, XP002522289, ISSN: 1530-6860 * |
Also Published As
Publication number | Publication date |
---|---|
IL170710A0 (en) | 2011-08-01 |
AU2004220607A1 (en) | 2004-09-23 |
JP2006519875A (en) | 2006-08-31 |
MXPA05009435A (en) | 2005-11-23 |
BRPI0408113A (en) | 2006-03-01 |
WO2004080393A2 (en) | 2004-09-23 |
CN1780616B (en) | 2010-05-12 |
WO2004080393A3 (en) | 2004-12-02 |
KR20050109971A (en) | 2005-11-22 |
KR100831545B1 (en) | 2008-05-21 |
CN1780616A (en) | 2006-05-31 |
EP1605935A2 (en) | 2005-12-21 |
AU2004220607B2 (en) | 2009-06-11 |
NZ542408A (en) | 2009-03-31 |
ZA200507322B (en) | 2007-03-28 |
CA2517845A1 (en) | 2004-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL175074A0 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatement, modification and management of pain | |
IL165258A0 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
EP1471909A4 (en) | Pharmaceutical composition and method for treating disorders of the central nervous system | |
EP1755654A4 (en) | Methods and systems for treatment of neurological diseases of the central nervous system | |
AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
EP1816990A4 (en) | Systems, devices and methods for treatment of intervertebral disorders | |
IL177861A0 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system | |
HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
IL178142A0 (en) | Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders | |
IL170710A0 (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
EP1567154A4 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
HUP0501017A3 (en) | Methods and compositions for treatment of central nervous system disorders | |
EP1699431A4 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
ZA200503241B (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
IL179038A0 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
IL176453A0 (en) | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases | |
EP1534295A4 (en) | Formulations and methods of administration of cephalotaxines, including homoharringtonine | |
AU2003300409A1 (en) | Word scramble games for stimulating brain and physical health | |
EP1569903A4 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases | |
EP1744748A4 (en) | Method of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myelodysplastic syndromes | |
IL179040A0 (en) | Methods of using and compositions comrpising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases | |
PL376756A1 (en) | Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
EP1567148A4 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration | |
EP1539100A4 (en) | Composition and methods for the treatment of skin disorders | |
AU2003202255A8 (en) | Compositions for treatment of central nervous system neoplasms, and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050929 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CELGENE CORPORATION |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090421 |
|
17Q | First examination report despatched |
Effective date: 20091014 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20101119 |